193 related articles for article (PubMed ID: 8405016)
21. Lack of a pharmacokinetic interaction between lansoprazole or pantoprazole and theophylline.
Pan WJ; Goldwater DR; Zhang Y; Pilmer BL; Hunt RH
Aliment Pharmacol Ther; 2000 Mar; 14(3):345-52. PubMed ID: 10735929
[TBL] [Abstract][Full Text] [Related]
22. Pharmacokinetics and pharmacodynamics of the direct oral thrombin inhibitor dabigatran in healthy elderly subjects.
Stangier J; Stähle H; Rathgen K; Fuhr R
Clin Pharmacokinet; 2008; 47(1):47-59. PubMed ID: 18076218
[TBL] [Abstract][Full Text] [Related]
23. Pharmacodynamics and kinetics of omeprazole MUPS 20 mg and pantoprazole 40 mg during repeated oral administration in Helicobacter pylori-negative subjects.
Geus WP; Mathôt RA; Mulder PG; Lamers CB
Aliment Pharmacol Ther; 2000 Aug; 14(8):1057-64. PubMed ID: 10930900
[TBL] [Abstract][Full Text] [Related]
24. Comparison of the pharmacodynamics and pharmacokinetics of pantoprazole (40 mg) as compared to omeprazole MUPS (20 mg) after repeated oral dose administration.
Ehrlich A; Lücker PW; Wiedemann A; Sander P; Huber R; Mascher H
Methods Find Exp Clin Pharmacol; 1999; 21(1):47-51. PubMed ID: 10222447
[TBL] [Abstract][Full Text] [Related]
25. Lack of influence of pantoprazole on the disposition kinetics of theophylline in man.
Schulz HU; Hartmann M; Steinijans VW; Huber R; Lührmann B; Bliesath H; Wurst W
Int J Clin Pharmacol Ther; 1996 May; 34(1 Suppl):S51-7. PubMed ID: 8793603
[TBL] [Abstract][Full Text] [Related]
26. Lack of interaction between pantoprazole and digoxin at therapeutic doses in man.
Hartmann M; Huber R; Bliesath H; Steinijans VW; Koch HJ; Wurst W; Kunz K
Int J Clin Pharmacol Ther; 1995 Sep; 33(9):481-5. PubMed ID: 8520804
[TBL] [Abstract][Full Text] [Related]
27. Metabolic disposition of pantoprazole, a proton pump inhibitor, in relation to S-mephenytoin 4'-hydroxylation phenotype and genotype.
Tanaka M; Ohkubo T; Otani K; Suzuki A; Kaneko S; Sugawara K; Ryokawa Y; Hakusui H; Yamamori S; Ishizaki T
Clin Pharmacol Ther; 1997 Dec; 62(6):619-28. PubMed ID: 9433390
[TBL] [Abstract][Full Text] [Related]
28. Differences in pH-dependent activation rates of substituted benzimidazoles and biological in vitro correlates.
Kromer W; Krüger U; Huber R; Hartmann M; Steinijans VW
Pharmacology; 1998 Feb; 56(2):57-70. PubMed ID: 9494064
[TBL] [Abstract][Full Text] [Related]
29. No influence of pantoprazole on the pharmacokinetics of phenytoin.
Middle MV; Müller FO; Schall R; Groenewoud G; Hundt HK; Huber R; Bliesath H; Steinijans VW
Int J Clin Pharmacol Ther; 1995 May; 33(5):304-7. PubMed ID: 7655771
[TBL] [Abstract][Full Text] [Related]
30. Pharmacokinetic profile of the oral direct thrombin inhibitor dabigatran etexilate in healthy volunteers and patients undergoing total hip replacement.
Stangier J; Eriksson BI; Dahl OE; Ahnfelt L; Nehmiz G; Stähle H; Rathgen K; Svärd R
J Clin Pharmacol; 2005 May; 45(5):555-63. PubMed ID: 15831779
[TBL] [Abstract][Full Text] [Related]
31. Replacement of oral proton pump inhibitors with intravenous pantoprazole to effectively control gastric acid hypersecretion in patients with Zollinger-Ellison syndrome.
Metz DC; Forsmark C; Lew EA; Starr JA; Soffer EF; Bochenek W; Pisegna JR
Am J Gastroenterol; 2001 Dec; 96(12):3274-80. PubMed ID: 11774936
[TBL] [Abstract][Full Text] [Related]
32. Pharmacokinetics of pantoprazole in patients with moderate and severe hepatic dysfunction.
Ferron GM; Preston RA; Noveck RJ; Pockros P; Mayer P; Getsy J; Turner M; Abell M; Paul J
Clin Ther; 2001 Aug; 23(8):1180-92. PubMed ID: 11558857
[TBL] [Abstract][Full Text] [Related]
33. Pentagastrin-stimulated gastric acid secretion and pharmacokinetics following single and repeated intravenous administration of the gastric H+, K(+)-ATPase-inhibitor pantoprazole (BY1023/SK&F96022) in healthy volunteers.
Simon B; Müller P; Hartmann M; Bliesath H; Lühmann R; Huber R; Bohnenkamp W; Wurst W
Z Gastroenterol; 1990 Sep; 28(9):443-7. PubMed ID: 2177296
[TBL] [Abstract][Full Text] [Related]
34. Pantoprazole does not interact with nifedipine in man under steady-state conditions.
Bliesath H; Huber R; Steinijans VW; Koch HJ; Kunz K; Wurst W
Int J Clin Pharmacol Ther; 1996 May; 34(1 Suppl):S81-5. PubMed ID: 8793608
[TBL] [Abstract][Full Text] [Related]
35. Efficacy and safety of pantoprazole in patients with gastroesophageal reflux disease using an intravenous-oral regimen. Austrian Intravenous Pantoprazole Study Group.
Wurzer H; Schutze K; Bethke T; Fischer R; Luhmann R; Riesenhuber C
Hepatogastroenterology; 1999; 46(27):1809-15. PubMed ID: 10430350
[TBL] [Abstract][Full Text] [Related]
36. Stereoselective chiral inversion of pantoprazole enantiomers after separate doses to rats.
Masubuchi N; Yamazaki H; Tanaka M
Chirality; 1998; 10(8):747-53. PubMed ID: 9803530
[TBL] [Abstract][Full Text] [Related]
37. Lack of pharmacokinetic interaction between pantoprazole and diclofenac.
Bliesath H; Huber R; Steinijans VW; Koch HJ; Wurst W; Mascher H
Int J Clin Pharmacol Ther; 1996 Apr; 34(4):152-6. PubMed ID: 8861733
[TBL] [Abstract][Full Text] [Related]
38. Pharmacokinetics and effect on caffeine metabolism of the proton pump inhibitors, omeprazole, lansoprazole, and pantoprazole.
Andersson T; Holmberg J; Röhss K; Walan A
Br J Clin Pharmacol; 1998 Apr; 45(4):369-75. PubMed ID: 9578184
[TBL] [Abstract][Full Text] [Related]
39. Lack of interaction between pantoprazole and digoxin at therapeutic doses in man.
Hartmann M; Huber R; Bliesath H; Steinijans VW; Koch HJ; Wurst W; Kunz K
Int J Clin Pharmacol Ther; 1996 May; 34(1 Suppl):S67-71. PubMed ID: 8793605
[TBL] [Abstract][Full Text] [Related]
40. Pantoprazole: an update of its pharmacological properties and therapeutic use in the management of acid-related disorders.
Cheer SM; Prakash A; Faulds D; Lamb HM
Drugs; 2003; 63(1):101-33. PubMed ID: 12487624
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
